Dr. Adam Kaplin is a neuropsychiatrist in Baltimore, caring for patients with central nervous system (CNS) neuroinflammatory diseases, such as multiple sclerosis (MS) and related MS spectrum diseases. As one of the few psychiatrists in the U.S. who specializes in MS, he treats people who have MS and other CNS neuroinflammatory diseases with neuropsychiatric symptoms. Patients travel from all over the country – and as far away as the Middle East – to see him. Dr. Kaplin is the principal psychiatric consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence and the clinical director of the Johns Hopkins Psychiatric Esketamine Clinic.
He graduated magna cum laude from Yale University before earning his M.D. and Ph.D. at Johns Hopkins, where he was a Medical Science Training Program awardee. He went on to complete an internship in internal medicine at Johns Hopkins Bayview Medical Center and a residency in psychiatry at Johns Hopkins Hospital, where he served as the chief resident of psychiatry.
Dr. Kaplin performs both pre-clinical and clinical research on the biological basis of immune-mediated mood disorders and cognitive impairment, with the goal of elucidating novel therapeutic strategies for neuroinflammatory and neurodegenerative disorders.
To enhance his clinical research, he has become progressively more involved in health information technology, especially as it applies to mental health care and research. He invented and co-developed a mobile, automated, SMS- and web-based platform (www.mood247.com) that serves as both a patient electronic diary and HIPAA-compliant virtual chart that facilitates patient, family and health care provider collaboration of care. He has also been involved in the testing of other novel technologies, such as the DANA tablet-based software that provides exquisitely sensitive and reliable mobile cognitive assessment.
Dr. Kaplin serves as review editor of Frontiers in Neurology, Frontiers in Neuroscience and Frontiers in Psychiatry.